重新发现硝基喹啉：一种桥接感染和癌症的金属螯合剂。

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-06-26 DOI:10.1016/j.drudis.2025.104419

Praveen Papareddy , Sophie R.M. Mielke , Marlowe Graham , Dennis Bachmann , Ewgenij Proschak , Thomas A. Wichelhaus , Kerstin Sander , Heiko Herwald

{"title":"重新发现硝基喹啉：一种桥接感染和癌症的金属螯合剂。","authors":"Praveen Papareddy , Sophie R.M. Mielke , Marlowe Graham , Dennis Bachmann , Ewgenij Proschak , Thomas A. Wichelhaus , Kerstin Sander , Heiko Herwald","doi":"10.1016/j.drudis.2025.104419","DOIUrl":null,"url":null,"abstract":"<div><div>Nitroxoline, a legacy antimicrobial agent, is gaining attention for its potential repurposing in infectious diseases and oncology. Its broad-spectrum activity, including biofilm disruption and metal-chelating properties, supports diverse therapeutic applications. However, its systemic use is limited by rapid urinary excretion, short plasma half-life, and limited tissue distribution. In this review, we summarize recent advances in understanding the mechanisms of action, cross-kingdom activity, and anticancer effects of nitroxoline. Despite encouraging preclinical data, clinical translation is constrained by pharmacokinetic (PK) and regulatory challenges. As interest in repurposing established drugs grows, nitroxoline presents a compelling candidate for integration into modern therapeutic strategies across infectious and neoplastic disease domains.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 8","pages":"Article 104419"},"PeriodicalIF":7.5000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rediscovering nitroxoline: a metal-chelating agent bridging infection and cancer\",\"authors\":\"Praveen Papareddy , Sophie R.M. Mielke , Marlowe Graham , Dennis Bachmann , Ewgenij Proschak , Thomas A. Wichelhaus , Kerstin Sander , Heiko Herwald\",\"doi\":\"10.1016/j.drudis.2025.104419\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Nitroxoline, a legacy antimicrobial agent, is gaining attention for its potential repurposing in infectious diseases and oncology. Its broad-spectrum activity, including biofilm disruption and metal-chelating properties, supports diverse therapeutic applications. However, its systemic use is limited by rapid urinary excretion, short plasma half-life, and limited tissue distribution. In this review, we summarize recent advances in understanding the mechanisms of action, cross-kingdom activity, and anticancer effects of nitroxoline. Despite encouraging preclinical data, clinical translation is constrained by pharmacokinetic (PK) and regulatory challenges. As interest in repurposing established drugs grows, nitroxoline presents a compelling candidate for integration into modern therapeutic strategies across infectious and neoplastic disease domains.</div></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"30 8\",\"pages\":\"Article 104419\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644625001321\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001321","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

硝基喹啉是一种传统的抗菌剂，因其在感染性疾病和肿瘤学中的潜在用途而受到关注。其广谱活性，包括生物膜破坏和金属螯合特性，支持多种治疗应用。然而，它的全身使用受到尿排泄迅速、血浆半衰期短和组织分布有限的限制。本文就硝基喹啉的作用机制、跨界活性和抗癌作用等方面的研究进展进行综述。尽管临床前数据令人鼓舞，但临床翻译受到药代动力学（PK）和监管挑战的限制。随着人们对现有药物重新利用的兴趣日益增长，硝基喹啉成为整合感染性和肿瘤性疾病领域现代治疗策略的一个引人注目的候选者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Rediscovering nitroxoline: a metal-chelating agent bridging infection and cancer

查看原文本刊更多论文

Rediscovering nitroxoline: a metal-chelating agent bridging infection and cancer

Nitroxoline, a legacy antimicrobial agent, is gaining attention for its potential repurposing in infectious diseases and oncology. Its broad-spectrum activity, including biofilm disruption and metal-chelating properties, supports diverse therapeutic applications. However, its systemic use is limited by rapid urinary excretion, short plasma half-life, and limited tissue distribution. In this review, we summarize recent advances in understanding the mechanisms of action, cross-kingdom activity, and anticancer effects of nitroxoline. Despite encouraging preclinical data, clinical translation is constrained by pharmacokinetic (PK) and regulatory challenges. As interest in repurposing established drugs grows, nitroxoline presents a compelling candidate for integration into modern therapeutic strategies across infectious and neoplastic disease domains.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.